Of the respondents indicating their clinic practices immunotherapy (n = 133), 12% indicated their clinic uses genomic sequencing to assess tumor mutational burden prior to immunotherapy administration, 44% indicated that their clinic conducts PD-L1 testing prior to immunotherapy administration (testing occurs either within the clinic or at an external site) and 53% reported their clinic having easy access to immunotherapy (Figure 2). This evidence concerns the gene CD274 and neoplasm.